Quan-Jiang Zhang

Quan-Jiang Zhang

Auto-generated profile, based on publicly available information

Quan-Jiang Zhang

Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
QZQuan-Jiang Zhang
Quan-Jiang Zhang
WHWilliam L. Holland
William L. Holland
LWLloyd Wilson
Lloyd Wilson
JTJason M. Tanner
Jason M. Tanner
DKDevin Kearns
Devin Kearns
J. David SymonsJ. David Symons
J. David Symons
Vascular dysfunction that accompanies obesity and insulin resistance may be mediated by lipid metabolites. We sought to determine if vascular ceramide leads to arterial dysfunction and to elucidate the underlying mechanisms. Pharmacological inhibition of de novo ceramide synthesis, using the Ser palmitoyl transferase inhibitor myriocin, and heterozygous deletion of dihydroceramide desaturase prevented vascular dysfunction and hypertension in mice after high-fat feeding. These findings were recapitulated in isolated arteries in vitro, confirming that ceramide impairs endothelium-dependent vasorelaxation in a tissue-autonomous manner. Studies in endothelial cells reveal that de novo ceramide biosynthesis induced protein phosphatase 2A (PP2A) association directly with the endothelial nitric oxide synthase (eNOS)/Akt/Hsp90 complex that was concurrent with decreased basal and agonist-stimulated eNOS phosphorylation. PP2A attenuates eNOS phosphorylation by preventing phosphorylation of the pool of Akt that colocalizes with eNOS and by dephosphorylating eNOS. Ceramide decreased the association between PP2A and the predominantly cytosolic inhibitor 2 of PP2A. We conclude that ceramide mediates obesity-related vascular dysfunction by a mechanism that involves PP2A-mediated disruption of the eNOS/Akt/Hsp90 signaling complex. These results provide important insight into a pathway that represents a novel target for reversing obesity-related vascular dysfunction.

8 May 2009 in Circulation Research
Verified
Journal Article
Closed access
PDF file
J. David SymonsJ. David Symons
J. David Symons
SMShawna L. McMillin
Shawna L. McMillin
CRChristian Riehle
Christian Riehle
JTJason Tanner
Jason Tanner
MPMilda Palionyte
Milda Palionyte
EAE. Dale Abel
E. Dale Abel
Impaired insulin signaling via phosphatidylinositol 3-kinase/Akt to endothelial nitric oxide synthase (eNOS) in the vasculature has been postulated to lead to arterial dysfunction and hypertension in obesity and other insulin resistant states. To investigate this, we compared insulin signaling in the vasculature, endothelial function, and systemic blood pressure in mice fed a high-fat (HF) diet to mice with genetic ablation of insulin receptors in all vascular tissues (TTr-IR−/−) or mice with genetic ablation of Akt1 (Akt1−/−). HF mice developed obesity, impaired glucose tolerance, and elevated free fatty acids that was associated with endothelial dysfunction and hypertension. Basal and insulin-mediated phosphorylation of extracellular signal-regulated kinase 1/2 and Akt in the vasculature was preserved, but basal and insulin-stimulated eNOS phosphorylation was abolished in vessels from HF versus lean mice. In contrast, basal vascular eNOS phosphorylation, endothelial function, and blood pressure were normal despite absent insulin-mediated eNOS phosphorylation inTTr-IR−/−mice and absent insulin-mediated eNOS phosphorylation via Akt1 in Akt1−/− mice. In cultured endothelial cells, 6 hours of incubation with palmitate attenuated basal and insulin-stimulated eNOS phosphorylation and NO production despite normal activation of extracellular signal-regulated kinase 1/2 and Akt. Moreover, incubation of isolated arteries with palmitate impaired endothelium-dependent but not vascular smooth muscle function. Collectively, these results indicate that lower arterial eNOS phosphorylation, hypertension, and vascular dysfunction following HF feeding do not result from defective upstream signaling via Akt, but from free fatty acid-mediated impairment of eNOS phosphorylation.

1 March 2015 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
BJBharat Jaishy
Bharat Jaishy
QZQuanjiang Zhang
Quanjiang Zhang
HCHeaseung S. Chung
Heaseung S. Chung
CRChristian Riehle
Christian Riehle
JSJamie Soto
Jamie Soto
EAE. Dale Abel
E. Dale Abel
Bharat Jaishy, Quanjiang Zhang, Heaseung S. Chung, Christian Riehle, Jamie Soto, Stephen Jenkins, Patrick Abel, L. Ashley Cowart, Jennifer E. Van Eyk, E. Dale Abel

7 August 2015 in Diabetes
Verified
Journal Article
Open access
PDF file
LBLeena P. Bharath
Leena P. Bharath
TRTing Ruan
Ting Ruan
YLYouyou Li
Youyou Li
ARAnindita Ravindran
Anindita Ravindran
XWXin Wan
Xin Wan
J. David SymonsJ. David Symons
J. David Symons
Prior studies have implicated accumulation of ceramide in blood vessels as a basis for vascular dysfunction in diet-induced obesity via a mechanism involving type 2 protein phosphatase (PP2A) dephosphorylation of endothelial nitric oxide synthase (eNOS). The current study sought to elucidate the mechanisms linking ceramide accumulation with PP2A activation and determine whether pharmacological inhibition of PP2A in vivo normalizes obesity-associated vascular dysfunction and limits the severity of hypertension. We show in endothelial cells that ceramide associates with the inhibitor 2 of PP2A (I2PP2A) in the cytosol, which disrupts the association of I2PP2A with PP2A leading to its translocation to the plasma membrane. The increased association between PP2A and eNOS at the plasma membrane promotes dissociation of an Akt-Hsp90-eNOS complex that is required for eNOS phosphorylation and activation. A novel small-molecule inhibitor of PP2A attenuated PP2A activation, prevented disruption of the Akt-Hsp90-eNOS complex in the vasculature, preserved arterial function, and maintained normal blood pressure in obese mice. These findings reveal a novel mechanism whereby ceramide initiates PP2A colocalization with eNOS and demonstrate that PP2A activation precipitates vascular dysfunction in diet-induced obesity. Therapeutic strategies targeted to reducing PP2A activation might be beneficial in attenuating vascular complications that exist in the context of type 2 diabetes, obesity, and conditions associated with insulin resistance.

30 July 2009 in The Journal of Physiology
Verified
Journal Article
Closed access
QZQuan‐Jiang Zhang
Quan‐Jiang Zhang
SMShawna L. McMillin
Shawna L. McMillin
JTJason M. Tanner
Jason M. Tanner
MPMilda Palionyte
Milda Palionyte
EAE. Dale Abel
E. Dale Abel
J. David SymonsJ. David Symons
J. David Symons

16 May 2007 in Apoptosis
Verified
Journal Article
Closed access
PDF file
KZKun-Ru Zhang
Kun-Ru Zhang
HLHai-Tao Liu
Hai-Tao Liu
HZHai-Feng Zhang
Hai-Feng Zhang
QZQuan-Jiang Zhang
Quan-Jiang Zhang
QLQiu-Xia Li
Qiu-Xia Li
Feng GaoFeng Gao
Feng Gao